The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rammensee, H. G.
Right arrow Articles by Bevan, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rammensee, H. G.
Right arrow Articles by Bevan, M. J.

The Journal of Immunology, Vol 133, Issue 5 2390-2396, Copyright © 1984 by American Association of Immunologists

ARTICLES

Functional clonal deletion of class I-specific cytotoxic T lymphocytes by veto cells that express antigen

HG Rammensee, PJ Fink and MJ Bevan

Intravenous injection of class I incompatible spleen cells into mice results in a drastic reduction of the recipient's cytotoxic T lymphocyte (CTL) response against the injected, but not against third party, class I antigens when measured in bulk cultures initiated 5 to 6 days after the injection. This specific suppressive effect is partly due to T cells but can also be seen when high numbers of anti-Thy-1 and complement-treated spleen cells of nude mice are injected. Such cells suppressing CTL responses against self histocompatibility antigens are called "veto cells." The precursor frequency of CTL specific for the injected class I antigen is found to be reduced greater than 200-fold at days 5 to 6 after the injection, whereas the frequencies of CTL specific for third party class I antigens are not significantly changed. These results indicate that there is a functional clonal deletion of the CTL recognizing class I incompatible veto cells in vivo. The role of such a veto phenomenon in the induction and maintenance of self tolerance and allograft tolerance is discussed.


This article has been cited by other articles:


Home page
 J. Virol.Home page
R. F. Rich and W. R. Green
Antiretroviral Cytolytic T-Lymphocyte Nonresponsiveness: FasL/Fas-Mediated Inhibition of CD4+ and CD8+ Antiviral T Cells by Viral Antigen-Positive Veto Cells
J. Virol., May 1, 1999; 73(5): 3826 - 3834.
[Abstract] [Full Text]

Home page
 BloodHome page
P. T. Daniel, A. Kroidl, J. Kopp, I. Sturm, G. Moldenhauer, B. Dorken, and A. Pezzutto
Immunotherapy of B-Cell Lymphoma With CD3x19 Bispecific Antibodies: Costimulation via CD28 Prevents "Veto" Apoptosis of Antibody-Targeted Cytotoxic T Cells
Blood, December 15, 1998; 92(12): 4750 - 4757.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
J. D. Hosenpud, J. P. Everett, T. E. Morris, K. A. Mauck, G. D. Shipley, and C. R. Wagner
Cardiac Allograft Vasculopathy : Association With Cell-Mediated but Not Humoral Alloimmunity to Donor-Specific Vascular Endothelium
Circulation, July 15, 1995; 92(2): 205 - 211.
[Abstract] [Full Text]

Home page
 ScienceHome page
H Schild, O Rotzschke, H Kalbacher, and H. Rammensee
Limit of T cell tolerance to self proteins by peptide presentation
Science, March 30, 1990; 247(4950): 1587 - 1589.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1984 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1984 by The American Association of Immunologists, Inc. All rights reserved.